ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
  • Abstract Number: 297
    S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
  • Abstract Number: 2948
    S100 Proteins Induce Canonical Wnt Signaling, Which Causes Increased Expression of MMPs in the Synovium
  • Abstract Number: 2952
    S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium
  • Abstract Number: 2764
    S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
  • Abstract Number: 1895
    Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
  • Abstract Number: 2822
    Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
  • Abstract Number: 852
    Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
  • Abstract Number: 949
    Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study
  • Abstract Number: 2234
    Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis.  a Prospective Randomized Double-Blinded Study
  • Abstract Number: 8
    Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
  • Abstract Number: 2285
    Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
  • Abstract Number: 1297
    Safety and Efficacy of Rituximab in Pediatric Lupus and Other Rheumatic Diseases
  • Abstract Number: L4
    Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 874
    Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
  • Abstract Number: 665
    Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
  • Abstract Number: 1492
    Safety and Tolerability of NNC0114­0006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
  • Abstract Number: 718
    Safety of Gardasil® Vaccine in Systemic Lupus Erythematosu, Trial Update
  • Abstract Number: 2376
    Safety of Rapid Rituximab Infusion in Rheumatoid Arthritis in a Single Community Practice
  • Abstract Number: 469
    Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
  • Abstract Number: 1319
    Safety of Rituximab in Treating Pediatric Rheumatologic Disease
  • Abstract Number: 243
    Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study
  • Abstract Number: 847
    Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy
  • Abstract Number: 1836
    Safety of Zoster Vaccination Administration in Rheumatic Patients  on Current Biologic Therapy
  • Abstract Number: 470
    Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
  • Abstract Number: 951
    Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
  • Abstract Number: 527
    Salivary Expression of S100A7/Psoriasin and Oral Damage in Primary Sjögren’s Syndrome and Overlapping Disorders
  • Abstract Number: 347
    Salt Aggravates Arthritis By Th17 Polarization
  • Abstract Number: 876
    SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study
  • Abstract Number: 1412
    Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study
  • Abstract Number: 735
    Sarcopenia in Systemic Sclerosis: Prevalence and Association with Functional Parameters and Quality of Life
  • Abstract Number: 2862
    Satisfaction Following Total Knee Replacement: Journey or Destination?
  • Abstract Number: 1156
    Satisfaction with Rural Rheumatology Telehealth Service
  • Abstract Number: 1187
    Scoring of Spinal Lesions Compatible with Axial Spondyloarthritis on MRI in Clinical Practice By Local Radiologist or Rheumatologist in Desir; Comparison with Central Reading
  • Abstract Number: 1425
    Screening Behavior and Prevalence of Hepatitis C Virus in Mexico
  • Abstract Number: 2998
    Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
  • Abstract Number: 1583
    Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp
  • Abstract Number: 2429
    Seasonal Changes May Influence Activity of Rheumatoid Arthritis
  • Abstract Number: 568
    Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
  • Abstract Number: L1
    Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
  • Abstract Number: 953
    Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
  • Abstract Number: 537
    Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
  • Abstract Number: 954
    Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
  • Abstract Number: 538
    Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
  • Abstract Number: 819
    Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
  • Abstract Number: 536
    Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
  • Abstract Number: 550
    Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
  • Abstract Number: 2944
    Sedentary Time Is an Independent Risk Factor for Disability Onset Among Adults at Elevated Risk: Prospective Cohort Study
  • Abstract Number: 1513
    Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
  • Abstract Number: 267
    Selective and Peripheral-Specific Trk Inhibitor Shows Potent Analgesic Effect Comparable to Morphine in Rat Osteoarthritis Model without CNS Toxicity
  • Abstract Number: 2184
    Selective Consumption of C2 Component in HCV Patients
  • Abstract Number: 391
    Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer
  • Abstract Number: 173
    Self-Management Education for Patients with Gout: A Review of Existing Resources
  • Abstract Number: 2164
    Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of ‘anti-inflammatory’ Myeloid-Derived Suppressor Cells (MDSC)
  • Abstract Number: 2663
    Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus
  • Abstract Number: 2142
    Sensitivity and Precision of Automated Osteophyte Volumetric Measurement in Knee Osteoarthritis over Four Years
  • Abstract Number: 2129
    Sensitivity and Specificity of the “Green Nail” Sign in Fluorescence Optical Imaging in Psoriatic Arthritis
  • Abstract Number: 353
    Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE
  • Abstract Number: 2141
    Sensitivity to Change of Joint Space Width Measurements in Hand Osteoarthritis in a Two Year Follow-up Study
  • Abstract Number: 1284
    Sensitivity to Change of Patient Preference Outcome Measures for Pain in Trials of Patients with Knee Osteoarthritis
  • Abstract Number: 2682
    Serine Arginine-Rich Splicing Factor 1 (SRSF1) Regulates Transcriptional Activation of the T Cell Receptor CD3 Zeta Chain in Human T Cells
  • Abstract Number: 1851
    Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
  • Abstract Number: 480
    Serious Infection Risk By Treatments and Types in Patients with RA
  • Abstract Number: 825
    Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
  • Abstract Number: 1248
    Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases
  • Abstract Number: 887
    Serological and Clinical Characteristics of a Large Collection of Incomplete Lupus Erythematosus Patients
  • Abstract Number: 407
    Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers
  • Abstract Number: 2212
    Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome
  • Abstract Number: 1639
    Serum Anti-Müllerian Hormone Levels in SLE Patients. the Disease Severity and Cyclophosphamide Reduce the Ovarian Reserve
  • Abstract Number: 2601
    Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab
  • Abstract Number: 534
    Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of  Anti-Ro Associated Congenital Heart Block
  • Abstract Number: 2099
    Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset
  • Abstract Number: 368
    Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
  • Abstract Number: 136
    Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis
  • Abstract Number: 1860
    Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis
  • Abstract Number: 988
    Serum CXCL13 As a Biomarker of Disease Activity and Severity in Rheumatoid Arthritis: Comparison with Acute Phase Reactants and the Autoantibody Profile
  • Abstract Number: 523
    Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
  • Abstract Number: 1653
    Serum Cystatin C As a Biomarker for Clinical Practice in Patients with Lupus Nephritis
  • Abstract Number: 807
    Serum Cytokine Profiles in Takayasu’s Arteritis: A Search for a Biomarker
  • Abstract Number: 1598
    Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
  • Abstract Number: 736
    Serum Galectin-3 Levels in Early Diffuse Systemic Sclerosis and the Relationship to Skin Score and Skin Score Change
  • Abstract Number: 2928
    Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
  • Abstract Number: 2582
    Serum Levels of Bone Morphogenetic Protein-7 and Sclerostin Are Elevated in Ankylosing Spondylitis, but Not Linked with Structural Damage
  • Abstract Number: 1715
    Serum Levels of CD163/Tweak Predict Risk of Digital Ulcers in Patients with Systemic Sclerosis
  • Abstract Number: 2925
    Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
  • Abstract Number: 2661
    Serum Neuronal Biomarkers and Brain Atrophy in Childhood-Onset Systemic Lupus Erythematosus
  • Abstract Number: 2515
    Serum Survivin in Early Rheumatoid Arthritis
  • Abstract Number: 1221
    Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
  • Abstract Number: 129
    Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice
  • Abstract Number: 2158
    Severe Neutropenia in Patients with Rheumatic Diseases at a Tertiary Care Hospital in South Korea
  • Abstract Number: 62
    Severe Spine Osteoarthritis in Older Men Is Associated with the Risk of Incident Fragility Fracture
  • Abstract Number: 2943
    Severity of Foot Pain Is Linked to the Prevalence of Depressive Symptoms: The Framingham Foot Study
  • Abstract Number: 189
    Sex Differences in Characteristics, Utilization and Outcomes of Patient Undergoing Total Elbow Arthroplasty: A Study of the U.S. Nationwide Inpatient Sample
  • Abstract Number: 1072
    Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis
  • Abstract Number: 1974
    Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon–gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts
  • Abstract Number: 2818
    SH2 Domain-Containing Phosphatase 2 Promotes Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes
  • Abstract Number: 617
    Shared HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis Among Three Ethnic Groups
  • Abstract Number: 2738
    Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
  • Abstract Number: 2611
    Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and  ankylosing  Spondylitis; Results from Turkbio Registry
  • Abstract Number: 1701
    Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
  • Abstract Number: 2603
    Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study
  • Abstract Number: 466
    Should Anti-Tnfa  treatment of RA be Stopped before Orthopedic Surgery?
  • Abstract Number: 2375
    Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
  • Abstract Number: 2739
    SHP-1 Regulates the Activation Threshold of iNKT Cells
  • Abstract Number: 307
    Sibling Exposure and Risk of Juvenile Idiopathic Arthritis
  • Abstract Number: 233
    Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
  • Abstract Number: 232
    Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
  • Abstract Number: 2123
    Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
  • Abstract Number: 877
    Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts
  • Abstract Number: 2393
    Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate  in Combination with Adalimumab
  • Abstract Number: 2413
    Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months
  • Abstract Number: 510
    Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
  • Abstract Number: 2596
    Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort
  • Abstract Number: 716
    Simple Disease Assessment for People with Lupus Erythematosus
  • Abstract Number: 1987
    Simulation in Continuing Education: Improving Evidence-Based Decisions for Rheumatoid Arthritis Management
  • Abstract Number: 1617
    Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes
  • Abstract Number: 284
    Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)– Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis
  • Abstract Number: 1325
    Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE): Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Localized Scleroderma and Juvenile Systemic Sclerosis
  • Abstract Number: 2540
    Sjö™, an Advanced Diagnostic Panel for Detection of Sjögren’s Syndrome Autoantibodies
  • Abstract Number: 1091
    Skeletal Muscle Fat and Its Association with Physical Function and Physical Activity in Adults with Rheumatoid Arthritis
  • Abstract Number: 964
    Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients
  • Abstract Number: 2843
    SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity
  • Abstract Number: 172
    Sleep Apnea and Risk of Incident Gout: A Population-Based Body-Mass Index Matched Cohort Study
  • Abstract Number: 570
    Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity
  • Abstract Number: 2833
    SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
  • Abstract Number: 894
    Small Fiber Neuropathy in Women with Fibromyalgia. a Clinical-Pathological Correlation Using Confocal Corneal Biomicroscopy
  • Abstract Number: 2524
    Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration
  • Abstract Number: 435
    Smoking Functions As a Negative Regulator of IGF-1 Levels and Adipokine Network in Patients with Rheumatoid Arthritis
  • Abstract Number: 2584
    Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis
  • Abstract Number: 348
    Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?
  • Abstract Number: 1068
    Smoking-Related Mortality in Rheumatoid Arthritis: A Retrospective Cohort Study Using Electronic Medical Records
  • Abstract Number: 2167
    Snapin Is Critical for Cathepsin D Activation and the Normal Lysosomal Function
  • Abstract Number: 1334
    Social Support and Suicidal Ideation in Systemic Lupus Erythematosus:  Georgians Organized Against Lupus Cohort
  • Abstract Number: 2120
    Societal Preferences for Rheumatoid Arthritis Treatments. Evidence from a Discrete Choice Experiment
  • Abstract Number: 1088
    Socioeconomic Disparities in Health Outcomes Among Individuals with, or at Risk for, Osteoarthritis from the United States: Data from the Osteoarthritis Initiative
  • Abstract Number: 978
    Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis
  • Abstract Number: 366
    Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis
  • Abstract Number: 409
    Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels
  • Abstract Number: 388
    Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
  • Abstract Number: 144
    Sonographic Differentiation of Heel Pain: Focal Degenerative Versus Systemic Inflammatory Enthesitis
  • Abstract Number: 119
    Sonographic Evaluation of the Fifth Metatarsophalangeal Joint Erosion in Rheumatoid Arthritis
  • Abstract Number: 151
    Sonographic Measurements Can be Misleading for Diagnosing Carpal Tunel Syndrome in Patients with Rheumatoid Arthritis
  • Abstract Number: 761
    Specific Autoantibody Profiles and Disease Subgroups Correlate with Circulating Micro-RNA in Systemic Sclerosis
  • Abstract Number: 2346
    Specific Overexpression of FPR2 (FPRL-1) on Th1 Cells in GPI-Induced Arthritis and Patients with Rheumatoid Arthritis
  • Abstract Number: 867
    Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
  • Abstract Number: 2566
    Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis
  • Abstract Number: 63
    Spine Osteoarthritis Is Associated with All Cause Mortality in Older Men
  • Abstract Number: 53
    Spine-Hip Diagnostic Discordance in the United Arab Emirates
  • Abstract Number: 1450
    Spironolactone As a Novel DMARD in Rheumatoid Arthritis
  • Abstract Number: 710
    Splenectomy in Systemic LUPUS Erythematosus and  AUTOIMMUNE Hematological Diseases. a Comparative Analysis
  • Abstract Number: 2829
    Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
  • Abstract Number: 1398
    Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal
  • Abstract Number: 443
    Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis
  • Abstract Number: 1761
    Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application
  • Abstract Number: 1858
    Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic
  • Abstract Number: 2319
    Standardizing and Documenting Patient Education and Disease Indices in Childhood-Onset Systemic Lupus Erythematosus
  • Abstract Number: 1777
    Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
  • Abstract Number: 663
    STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice
  • Abstract Number: 1033
    Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling
  • Abstract Number: 1815
    STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation
  • Abstract Number: 3009
    Stem Cell Augmentation for Cardiovascular Risk in Rheumatoid Arthritis
  • Abstract Number: 1457
    Stem Cell Growth Factor Expression in Rheumatoid Arthritis
  • Abstract Number: 2283
    Steroid-Sparing Effect of Anakinra (Kineret®) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome
  • Abstract Number: 33
    Stimulation of the Adenosine a2A receptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction
  • Abstract Number: L21
    Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13
  • Abstract Number: 2468
    Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
  • Abstract Number: 1080
    Stroke Risks Among U.S. Medicaid Recipients with Systemic Lupus Erythematosus, 2000-2006: Racial and Ethnic Variation
  • Abstract Number: 2463
    Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
  • Abstract Number: 1916
    Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice
  • Abstract Number: 566
    Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
  • Abstract Number: 1997
    Structured Integrative Rheumatology Modules (SIRM)
  • Abstract Number: 1379
    Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis
  • Abstract Number: 1268
    Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies
  • Abstract Number: 1533
    Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
  • Abstract Number: 1226
    Studying Patients with Autoinflammatory Diseases: The Past, Present, and a Perspective for the Future
  • Abstract Number: 1381
    Subaxial Cervical Spine Involvement in Symptomatic Rheumatoid Arthritis Patients: Comparison with Cervical Spondylosis
  • Abstract Number: 1818
    Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative
  • Abstract Number: 2127
    Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission
  • Abstract Number: 1184
    Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging
  • Abstract Number: 1300
    Subclinical Right Ventricle Systolic Dysfunction By Two-Dimensional Speckle-Tracking Echocardiography in Childhood-Onset Systemic Lupus Erythematosus Patients
  • Abstract Number: 152
    Subclinical Synovial Inflammation in Gout
  • Abstract Number: 1893
    Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
  • Abstract Number: 2192
    Successful Therapy with Intravenous Sodium Thiosulfate for Adult Dermatomyositis Associated Calcinosis
  • Abstract Number: 685
    Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors
  • Abstract Number: 1954
    Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice
  • Abstract Number: 322
    Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
  • Abstract Number: 1618
    Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties
  • Abstract Number: 1222
    Suppressive Effect of Butyrate on Monosodium Urate (MSU) Crystal-Induced IL-1beta Production Is Mediated Via Inhibition of Class I Histone Deacetylases
  • Abstract Number: 218
    Surface Area and Fatty Infiltration of Vastus Medialis Measured By Magnetic Resonance Imaging Are Risk Factors for the Progression of Knee Osteoarthritis and Discriminate Two Osteoarthritis Phenotypes
  • Abstract Number: 2106
    Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury
  • Abstract Number: 2995
    Surrogate Measures of Extent of Interstitial Lung Disease As Measured By Quantitative Radiographic Analysis in Patients with Systemic Sclerosis
  • Abstract Number: 2698
    Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status
  • Abstract Number: 1785
    Survival of Microscopic Polyangiitis (MPA) Patients with and without Pulmonary Fibrosis (PF)
  • Abstract Number: 2847
    Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis
  • Abstract Number: 1538
    Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line  for  All Rheumatoid Arthtritis Patients  Irrespective to the Inhibitor of Tumour Necrosis Factor  Previously Used
  • Abstract Number: 1526
    Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year Data 
  • Abstract Number: 552
    Sustained Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis
  • Abstract Number: 1521
    Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis
  • Abstract Number: 2560
    Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
  • Abstract Number: 1552
    Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis
  • Abstract Number: 11
    Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome
  • Abstract Number: 2394
    Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor
  • Abstract Number: 2391
    Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
  • Abstract Number: 1242
    Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
  • Abstract Number: 2271
    Symptom and Treatment Characteristics of Juvenile Primary Fibromyalgia Syndrome: Are Males and Females Created Equal?
  • Abstract Number: 892
    Symptom Increase in Fibromyalgia Is Not Consistent with the Central Sensitization or Central Hyperresponsiveness Hypothesis
  • Abstract Number: 2951
    Syndecan-4 Regulates Chondrocyte Phenotype and Cartilage Homeostasis Via the WNT Signaling Pathway
  • Abstract Number: 1036
    Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL-23
  • Abstract Number: 1472
    Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes
  • Abstract Number: 2950
    Synovial Macrophages Promote TGF-β Activation after Intra-Articular Injections of Oxidized LDL in Naïve Murine Knee Joints, Preventing Production of Pro-Inflammatory Factors S100A8/9, Chemokines and Aggrecanase-Induced Neo-Epitopes
  • Abstract Number: 1292
    Synovitis Characteristics and Associated Intra-Articular Pathology in a Cohort of Patients Undergoing Meniscectomy for Meniscal Tear
  • Abstract Number: 1100
    System Review: The Most Common Symptoms of Fibromyalgia Patients Other Than Pain, Fatigue, Insomnia, and Cognitive Dysfunction
  • Abstract Number: 2044
    Systematic Review of the Effect of Anti-Rheumatic Therapies upon Vaccine Immunogenicity
  • Abstract Number: 2906
    Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis
  • Abstract Number: 1429
    Systemic Inflammation in Alzheimer’s Disease:  Relevance to Patients with Rheumatoid Arthritis
  • Abstract Number: 2779
    Systemic Inflammatory and Autoimmune Manifestations Associated with Myelodysplastic Syndrome: A French Multicenter Retrospective Study
  • Abstract Number: 319
    Systemic Juvenile Idiopathic Arthritis and Exposure to Fine Particulate Air Pollution
  • Abstract Number: 2669
    Systemic Lupus Erythematosus and Lactation: Factors Affecting Infant Feeding Choices in Women with SLE
  • Abstract Number: 2622
    Systemic LUPUS Erythematosus in Spanish Males
  • Abstract Number: 1854
    Systemic Lupus Erythematosus Patients Have Increased Risk of Short Term Adverse Events after Total Hip Arthroplasty
  • Abstract Number: 1282
    Systemic Pain Modulation Is Related to Body Perception in People with Knee Osteoarthritis
  • Abstract Number: 747
    Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms
  • Abstract Number: 1691
    Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study
  • Abstract Number: 2707
    Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn
  • Abstract Number: 2226
    Systemic Treatment for Clinically Amyopathic Dermatomyositis
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology